ReviewJournal of gynecologic oncology2024
Targeting BRAF pathway in low-grade serous ovarian cancer.
Review in Journal of gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis.Future oncology (London, England) · 2025Pooled it
- Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.Future oncology (London, England) · 2025Pooled it
- Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials.Frontiers in pharmacology · 2024Pooled it
- Past and present: a bibliometric study on the treatment of recurrent ovarian cancer.Frontiers in pharmacology · 2024Pooled it
- The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway.Future science OA · 2026Article
- Prognostic Nomogram for Ovarian Cancer Patients on First-Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study.Cancer medicine · 2026Article
- FUS-stabilized USP7 facilitates the bevacizumab resistance of ovarian cancer through deubiquitinating PTK2.Journal of gynecologic oncology · 2026Article
- Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets.Frontiers in pharmacology · 2026Review
- Prognostic significance of tumour-infiltrating T lymphocytes in ovarian cancer: a protocol for systematic review and meta-analysis.BMJ open · 2025Article
- Silent Threat: Delayed Brain Metastasis After Successful Ovarian Cancer Therapy.Clinical case reports · 2025Article
- The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer.The journal of obstetrics and gynaecology research · 2025Article
- Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.Oncology and therapy · 2025Article
- Article
- Article
- The -124C>T Mutation of theCurrent oncology (Toronto, Ont.) · 2025Article
- CNTN1 promotes cell proliferation and metastasis in ovarian cancer through PSEN1.Translational cancer research · 2025Article
- Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance.International journal of molecular sciences · 2025Review
- Tumor Cell-Expressed Herpesvirus Entry Mediator Regulates Proliferation and Adaptive Immunity in Ovarian Cancer.Immunity, inflammation and disease · 2025Article
- Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.Oncology and therapy · 2025Article
- A novel machine learning-driven immunogenic cell death signature for predicting ovarian cancer prognosis.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in genes encoding for proteins along the RAS-RAF-MEK-ERK pathway have been detected in a variety of tumor entities including ovarian carcinomas. In the recent years, several inhibitors of this pathway have been developed, whose antitumor potential is currently being assessed in different clinical trials. Low grade serous ovarian carcinoma, is a rare gynecological tumor which shows favorable overall survival, compared to the general ovarian cancer population, but worrying resistance to conventional chemotherapies. The clinical behavior of low grade serous ovarian carcinoma reflects the different gene profile compared to high-grade serous carcinoma:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.